Hospital
Zhejiang Cancer Hospital中国科学院大学附属肿瘤医院(浙江省肿瘤医院)
At a glance
Published values only, each read from the record this page is built on. The listings behind them are in the section below.
-
Published research 12 PubMed records we hold for this hospital (the newest twenty per hospital)
-
Registered studies 29 records we hold for this hospital, as registered
Rankings & accreditation
These listings are published by the bodies that run them, not by this site. Every line carries the year it was published and a link to its source; this is not a paid or promoted listing.
Fudan specialty reputation ranking
| Item | Rank / tier | Year | Caliber | Source |
|---|---|---|---|---|
| Medical Oncology 肿瘤学 | #7 | 2023 | Place in the specialty reputation ranking | https://www.fdygs.com/news2023-1.aspx |
Conditions treated here
Conditions this site files under the specialties above. It is a record of the listings, not a recommendation.
For international patients
A line appears here only where we hold a record for it. A line that is missing has not been verified - ask us and we will put the question to the hospital.
Hospital details
- Chinese name
- 中国科学院大学附属肿瘤医院(浙江省肿瘤医院)
- English name
- Zhejiang Cancer Hospital
Values written in Chinese are quoted as published by the source.
The grade list reference is the date or review batch the official list was published under; it is quoted in the source's language.
Also known as
- ZJCH
- Cancer Hospital of the University of Chinese Academy of Sciences
Evidence for this condition
Selected using official public data sources
-
Colorectal cancer
Published research
- Targeting JOSD2 degrades β-catenin to suppress colorectal cancer metastasis by disrupting RAS/ERK/β-catenin axis. Acta pharmacologica Sinica, 2026
PubMed indexes 1 paper on this condition that names this hospital.
Also ranked: Medical Oncology #7 in the Fudan list.
-
Breast cancer
Published research
- Cost-effectiveness of inavolisib-based therapy in PIK3CA-mutated advanced breast cancer in the USA. Breast (Edinburgh, Scotland), 2026
PubMed indexes 1 paper on this condition that names this hospital.
Also ranked: Medical Oncology #7 in the Fudan list.
-
Lung cancer
Published research
- HECW2 suppresses non-small cell lung cancer progression by destabilizing SCNN1A and inactivating AKT/mTOR pathway. Biochemical pharmacology, 2026
- Clostridium Butyricum and butyrate enhance PD-1 inhibitor therapy in non-small cell lung cancer by regulating the HDAC1/ID2/IL-12R pathway. Translational oncology, 2026
1 more published study
PubMed indexes 3 papers on this condition that name this hospital.
Also ranked: Medical Oncology #7 in the Fudan list.
-
Liver cancer
Published research
- Reply to: Different Stage But Similar Survival in Hepatocellular Carcinoma: A Dilemma of Treatment Timing? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2026
PubMed indexes 1 paper on this condition that names this hospital.
Also ranked: Medical Oncology #7 in the Fudan list.
-
Stomach cancer
Published research
- Metabolic heterogeneity and functional diversity of cancer-associated fibroblasts in gastric cancer (Review). Oncology letters, 2026
- Lymph node response ratio complements tumor regression grade in prognostic stratification after neoadjuvant therapy for gastric cancer. Surgical oncology, 2026
2 more published studies
PubMed indexes 4 papers on this condition that name this hospital.
Also ranked: Medical Oncology #7 in the Fudan list.
-
Prostate cancer
Published research
- Gut microbial metabolism of Flutamide attenuates its therapeutic efficacy against prostate cancer. Gut microbes, 2026
PubMed indexes 1 paper on this condition that names this hospital.
Also ranked: Medical Oncology #7 in the Fudan list.
-
Nasopharyngeal carcinoma
Published research
- Validation and refinement of the N classification for nasopharyngeal carcinoma based on the 9th version AJCC/UICC TNM staging system in non-endemic regions of China: a multicenter cohort study. Clinical and translational radiation oncology, 2027
PubMed indexes 1 paper on this condition that names this hospital.
Also ranked: Medical Oncology #7 in the Fudan list.
-
Pancreatic cancer
Fudan specialty reputation ranking 2023
- Medical Oncology #7 https://www.fdygs.com/news2023-1.aspx
-
Bone and soft tissue sarcoma
Fudan specialty reputation ranking 2023
- Medical Oncology #7 https://www.fdygs.com/news2023-1.aspx
Other hospitals in Hangzhou
Source & evidence
- Source URL
- https://www.fdygs.com/news2023-1.aspx
- Source scheme
- https
- Source type
- Third-party compilation
- Evidence level
- B - hospital self-statement or authoritative media
- Retrieved on
- 2026-09-24